Q3 2020 Sales Performance
Innovation
Upcoming milestones that will inform our progress
2H 2020
Anticipated
submission
Nucala NP
Shingrix IC (US)
gsk
1H 2021
Benlysta + Rituxan SLE
dostarlimab (PD-1) dMMR pan-tumor
2H 2021
bintrafusp alfa (TGFß trap/anti-PDL1) BTC
Zejula + dostarlimab 2L+ PROC
(MOONSTONE)4
1H 2022
Dostarlimab (PD-1) combo with CT 1L EC
(RUBY)
daprodustat (HIF-PHI) anemia
2H 2022
belantamab mafodotin (BCMA) 3L in MM
(DREAMM-3)
cabotegravir HIV PrEP
4182136 (Vir-7831) COVID-19
MMR (US)
Pivotal data
Benlysta + Rituxan SLE¹
bintrafusp alfa BTC
dostarlimab (PD-1) dMMR pan-tumor
4182136 (Vir) COVID-193
PoC data
2330672 (linerixibat, IBAT inhibitor) cholestatic
pruritus in PBC2
belantamab mafodotin (BCMA) PD-1 combo in MM
(DREAMM-4)
COVID-19 (Clover Biopharmaceuticals)
COVID-19 (Medicago)
COVID-19 (Sanofi)
3359609 (ICOS) ENTRÉE lung platform -
docetaxel
2831781 (aLAG3 depleting) UC*
otilimab (aGM-CSF) COVID-19
dostarlimab combo with CT 1L EC (RUBY)
Zejula + dostarlimab 2L+ PROC
(MOONSTONE)4
daprodustat anemia
belantamab mafodotin (BCMA) 3L in MM
(DREAMM-3)
gepotidacin uUTI5
belantamab mafodotin (BCMA) + Pd 2L+ in
MM (DREAMM-8)
MenABCWY
RSV older adults
RSV maternal
cobolimab (TIM-3) NSCLC (AMBER)
belantamab mafodotin (BCMA) 1L combo in MM
(DREAMM-9)
3036656 (leucyl t-RNA) tuberculosis*
3228836 (HBV-ASO) HBV²
lete-cel (3377794 NY-ESO) NSCLC* therapy
S. Aureus interim data*
*Interim Analysis (internal) 1. Primary data in-house at 52 weeks, study completion at 104 weeks 2. Phase 2b study 3. Also delivers PoC data 4. Study temporarily
held recruitment activities to perform a pre-planned interim analysis 5. interim analysis subject to regulators feedback 6. Initial data, timing dependent on RSV
infection circulation during pandemic lockdowns
Note: tick marks refer to programmes on left side of marks
Key:
+ve data in-house, decided to progress
+ve data in-house, decision pending
data in-house, additional data needed
-ve data in-house, return to research
* -ve data in-house, decided to terminate
MM: multiple myeloma; NP: nasal polyposis;
PrEP: pre-exposure prophylaxis; SLE:
systemic lupus erythematosus; UC: ulcerative
colitis; NSCLC: non-small cell lung cancer;
PBC: primary biliary cholangitis; EC:
endometrial cancer; PROC: Platinum
resistant ovarian cancer; BTC: biliary tract
cancer; dMMR: deficient mismatch repair
41View entire presentation